LUYE PHARMA (02186) rose nearly 5% in Hong Kong trading. At the time of writing, the stock was up 3.69% to HK$2.81, with a trading volume of HK$105 million. The catalyst for the movement was the company's 2025 earnings report, released on March 31. The report showed revenue increased by 4.1% year-on-year to RMB 6.308 billion. Profit attributable to shareholders reached approximately RMB 619 million, representing a significant year-on-year growth of 31.12%. Basic earnings per share were 15.88 fen. According to the announcement, the revenue growth was driven by increased sales and licensing income from certain products.